Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
$40.13
$0.08(0.16%)
At close: 4:00 PM EST
$40.13
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$32.99 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)2.73M
Market Cap
$4.22B
Enterprise Value$3.92B
Total Cash (Recent Filing)$421.68M
Total Debt (Recent Filing)$6.36M
Price to Earnings (P/E)43.8
Beta0.50
Next Earnings
Feb 18, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.16
Shares Outstanding105,188,220
10 Day Avg. Volume2,739,249
30 Day Avg. Volume2,731,938
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)7.65
Price to Sales (P/S)7.71
P/FCF Ratio26.55
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue5.28
Enterprise Value/Gross Profit5.38
Enterprise Value/Ebitda54.04
Forecast
1Y Price Target
$105.25Price Target Upside162.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPivotal trial data showed relacorilant plus chemotherapy significantly reduced risk of death versus chemotherapy alone while maintaining a comparable safety profile, supporting its potential as a meaningful new therapy in platinum‑resistant ovarian cancer.
Commercial Strength And ExclusivityKorlym sales continue to expand and management projects a multibillion‑dollar opportunity, while solid cash reserves plus patents and orphan‑drug designations offer financial runway and market protection during commercialization.
Regulatory OutlookNDA for relacorilant in platinum‑resistant ovarian cancer has a PDUFA date of July 11, 2026 and analysts assign a high probability of approval, which could enable a new commercial launch and revenue stream.
Bears Say
Distribution And Execution ChallengesDeparture of the exclusive distributor and ongoing specialty pharmacy transitions have disrupted distribution scale‑up, creating near‑term sales pressure and complicating commercialization plans.
Generic Competition RiskPotential generic competition from Teva poses a threat to Korlym market share and pricing, which could materially reduce revenue assumptions that underlie current valuation expectations.
Regulatory Setback And Trial RequirementsFDA issued a Complete Response Letter requesting additional confirmatory evidence for relacorilant, indicating the company will likely need another large trial and that approval and market entry could be delayed by multiple years.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $32.99 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $4.22B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Feb 18, 2026 which is in 12 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Nov 04, 2025. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.164 by -$0.004.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is 0.33.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 105,188,220 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.16 in its last earnings report, missing expectations of $0.164. Following the earnings report the stock price went up 7.806%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$105.25 (162.27% Upside)
$105.25 (162.27% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 343.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $364.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.0%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.02%
12-Months-Change
Fundamentals
Return on Equity
16.47%
Trailing 12-Months
Asset Growth
5.02%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and a robust pipeline, particularly in hypercortisolism and oncology. However, challenges such as a significant decline in net income and unresolved patent litigation present concerns.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$105.25
▲(162.27% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.68% Insiders
17.20% Mutual Funds
0.03% Other Institutional Investors
50.65% Public Companies and Individual Investors